Mohammed M. Dar

2.1k total citations
42 papers, 1.7k citations indexed

About

Mohammed M. Dar is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Mohammed M. Dar has authored 42 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 14 papers in Molecular Biology and 11 papers in Immunology. Recurrent topics in Mohammed M. Dar's work include Cancer Treatment and Pharmacology (13 papers), Microtubule and mitosis dynamics (9 papers) and Immunotherapy and Immune Responses (9 papers). Mohammed M. Dar is often cited by papers focused on Cancer Treatment and Pharmacology (13 papers), Microtubule and mitosis dynamics (9 papers) and Immunotherapy and Immune Responses (9 papers). Mohammed M. Dar collaborates with scholars based in United States, United Kingdom and Netherlands. Mohammed M. Dar's co-authors include Denis R. Patrick, Pearl S. Huang, Jeffrey R. Jackson, Jeffrey P. Hodge, A. Benjamin Suttle, Steven J. Kathman, Kevin Laubscher, John M. Kirkwood, Johann S. de Bono and Linda M. Thurmond and has published in prestigious journals such as Journal of Clinical Oncology, Nature reviews. Cancer and Cancer.

In The Last Decade

Mohammed M. Dar

42 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mohammed M. Dar United States	19	891	820	465	336	280	42	1.7k
Katherine G. Moss United States	15	1.2k 1.4×	666 0.8×	423 0.9×	182 0.5×	214 0.8×	17	1.9k
Scott A. Boerner United States	23	1.2k 1.3×	852 1.0×	275 0.6×	238 0.7×	337 1.2×	40	2.2k
Yukinori Minoshima Japan	17	1.2k 1.3×	504 0.6×	331 0.7×	133 0.4×	213 0.8×	35	1.9k
László Kopper Hungary	26	821 0.9×	512 0.6×	215 0.5×	146 0.4×	293 1.0×	81	1.6k
Yan Degenhardt United States	16	1.1k 1.2×	663 0.8×	362 0.8×	99 0.3×	190 0.7×	23	1.6k
Howard Fingert United States	23	765 0.9×	1.1k 1.3×	701 1.5×	100 0.3×	220 0.8×	47	1.9k
Maria E. Arango United States	15	1.2k 1.4×	1.1k 1.3×	207 0.4×	177 0.5×	695 2.5×	20	2.1k
Jeff Sosman United States	20	1.2k 1.3×	1.2k 1.4×	101 0.2×	498 1.5×	301 1.1×	38	2.2k
Jens Quant Austria	9	1.1k 1.3×	732 0.9×	684 1.5×	69 0.2×	562 2.0×	15	2.0k
Thomas Holbro Switzerland	11	1.3k 1.5×	1.3k 1.5×	120 0.3×	196 0.6×	300 1.1×	17	2.3k

Countries citing papers authored by Mohammed M. Dar

Since Specialization

Citations

This map shows the geographic impact of Mohammed M. Dar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohammed M. Dar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohammed M. Dar more than expected).

Fields of papers citing papers by Mohammed M. Dar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohammed M. Dar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohammed M. Dar. The network helps show where Mohammed M. Dar may publish in the future.

Co-authorship network of co-authors of Mohammed M. Dar

This figure shows the co-authorship network connecting the top 25 collaborators of Mohammed M. Dar. A scholar is included among the top collaborators of Mohammed M. Dar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohammed M. Dar. Mohammed M. Dar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hyman, David M., Naiyer A. Rizvi, Ronald B. Natale, et al.. (2018). Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. Clinical Cancer Research. 24(12). 2749–2757. 38 indexed citations

Wheatley‐Price, Paul, Shirish M. Gadgeel, Toshiaki Takahashi, et al.. (2018). Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 20(3). e362–e368. 5 indexed citations

Reardon, David A., Morris D. Groves, Patrick Y. Wen, et al.. (2013). A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma. Clinical Cancer Research. 19(4). 900–908. 91 indexed citations

Heath, Elisabeth I., Jeffrey R. Infante, Lionel D. Lewis, et al.. (2013). A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 71(3). 565–573. 29 indexed citations

Deng, Yanli, et al.. (2012). Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 43(5). 443–453. 72 indexed citations

Olmos, David, Douglas S. Barker, Rohini Sharma, et al.. (2011). Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 17(10). 3420–3430. 134 indexed citations

Fleming, Ronald A., Carolyn J. Bowen, Mohammed M. Dar, et al.. (2011). A Phase I Study of Capecitabine, Oxaliplatin, and Lapatinib in Metastatic or Advanced Solid Tumors. Clinical Colorectal Cancer. 10(1). 57–62. 7 indexed citations

Heath, Elisabeth I., E. Gabriela Chiorean, Christopher J. Sweeney, et al.. (2010). A Phase I Study of the Pharmacokinetic and Safety Profiles of Oral Pazopanib With a High-Fat or Low-Fat Meal in Patients With Advanced Solid Tumors. Clinical Pharmacology & Therapeutics. 88(6). 818–823. 85 indexed citations

Holen, Kyle D., Chandra P. Belani, George Wilding, et al.. (2010). A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. Cancer Chemotherapy and Pharmacology. 67(2). 447–454. 60 indexed citations

10.

Goh, Brian C., Nandi J. Reddy, Kevin Laubscher, et al.. (2010). An Evaluation of the Drug Interaction Potential of Pazopanib, an Oral Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, Using a Modified Cooperstown 5+1 Cocktail in Patients With Advanced Solid Tumors. Clinical Pharmacology & Therapeutics. 88(5). 652–659. 72 indexed citations

11.

Tarhini, Ahmad A., Michael Millward, Paul N. Mainwaring, et al.. (2009). A phase 2, randomized study of SB‐485232, rhIL‐18, in patients with previously untreated metastatic melanoma. Cancer. 115(4). 859–868. 94 indexed citations

12.

Oostendorp, Roos L., Sanjay Goel, Deborah A. Smith, et al.. (2009). Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors. International Journal of Clinical Pharmacology and Therapeutics. 47(3). 195–206. 3 indexed citations

13.

Burris, Howard A., Andreas du Bois, Afshin Dowlati, et al.. (2009). Abstract A6: Pazopanib combination with paclitaxel and carboplatin in patients with advanced solid tumors and gynecological cancers: Results of two phase I studies. Molecular Cancer Therapeutics. 8(12_Supplement). A6–A6. 4 indexed citations

14.

Blagden, Sarah P., David Olmos, Rakesh Kumar Sharma, et al.. (2008). Characterization of BI 6727, a novel Polo-like kinase inhibitor with a distinct pharmacokinetic profile and efficacy in a model of taxane-resistant colon cancer. European Journal of Cancer Supplements. 6. 135–135. 2 indexed citations

15.

Blagden, Sarah P., L. Rhoda Molife, Miranda Payne, et al.. (2008). A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours. British Journal of Cancer. 98(5). 894–899. 63 indexed citations

16.

Kathman, Steven J., et al.. (2008). A Bayesian population PK–PD model for ispinesib/docetaxel combination-induced myelosuppression. Cancer Chemotherapy and Pharmacology. 63(3). 469–476. 12 indexed citations

17.

Jackson, Jeffrey R., Denis R. Patrick, Mohammed M. Dar, & Pearl S. Huang. (2007). Targeted anti-mitotic therapies: can we improve on tubulin agents?. Nature reviews. Cancer. 7(2). 107–117. 388 indexed citations

18.

Dar, Mohammed M. & Larry W. Kwak. (2003). Vaccination strategies for lymphomas. Current Oncology Reports. 5(5). 380–386. 4 indexed citations

19.

Dar, Mohammed M., Zeinab Abdel-Wahab, Carol E. Vervaert, et al.. (1996). Immunological memory induced by genetically transduced tumor cells. Annals of Surgical Oncology. 3(3). 247–254. 7 indexed citations

20.

Abdel-Wahab, Zeinab, Mohammed M. Dar, Carol E. Vervaert, et al.. (1996). Effect of Irradiation on Cytokine Production, MHC Antigen Expression, and Vaccine Potential of Interleukin-2 and Interferon-γ Gene-Modified Melanoma Cells. Cellular Immunology. 171(2). 246–254. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact